Research programme: vaccines - Pevion Biotech

Drug Profile

Research programme: vaccines - Pevion Biotech

Alternative Names: Broadband influenza vaccine - Pevion; PEV 8

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Pevion Biotech
  • Class Subunit vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Influenza A virus infections
  • Discontinued Alzheimer's disease; Diphtheria; Malignant melanoma; Tetanus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-infections(Prevention) in Switzerland (Parenteral)
  • 31 Jan 2007 Preclinical trials in Candidiasis in Switzerland (Parenteral)
  • 11 May 2005 Preclinical trials in Respiratory syncytial virus infections in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top